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Abstract The activity of a number of 1-[3-(4-arylpi-
perazin-1-yl)propyl]pyrrolidin-2-one antiarrhythmic (AA)
agents was described using the quantitative structure–
activity relationship model by applying it to 33 compounds.
The molecular descriptors of the AA activity were obtained
by quantum chemical calculations combined with molec-
ular modeling calculations. The resulting model explains
up to 91% of the variance and it was successfully validated
by four tests (LOO, LMO, external test, and Y-scrambling
test). Statistical analysis shows that the AA activity of the
studied compounds depends mainly on the PCR and JGI4
descriptors.
Keywords 1-[3-(4-Arylpiperazin-1-yl)propyl]pyrrolidin-
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Introduction
a1-Adrenergic receptors (a1-AR) are members of the
G-proteincoupledsuperfamilyofreceptors,whichmodulate
intercellularbiochemicalprocessesinresponsetochangesin
the extracellular concentration of the neurotransmitter nor-
epinephrine and the circulating hormone epinephrine, lead-
ing to widespread physiological actions that make them
attractive targets for drug discovery (Becker et al., 2004;
Golan 2008;H eet al., 2008; Zhong and Minneman 1999).
Theyareresponsibleforanumberofphysiologicalfunctions
(Abbasetal.,2006;Grahametal.,1996;Piasciketal.,1999)
in:
(a) cardiovascular tissues regarding vascular smooth
contraction and blood pressure regulation,
(b) noncardiovascular tissues regarding the human pros-
tate smooth muscle contraction or the regulation of
cerebral microcirculation.
Thus, a1-AR antagonists can be useful in the treatment
of hypertension, benign prostatic hyperplasia (BPH), lower
urinary track symptoms (LUTS), or cardiac arrhythmia
(Carmeliet and Mubagwa, 1998; Chiu et al., 2008; Jain
et al., 2008; Koshimizu et al., 2007; Nargund and Grey,
2008; Thiyagarajan, 2002).
Now, in the globalization era, determined by speed,
uncertainty and instability people live in increasing stress
leading to a rise in the incidence of cardiovascular diseases.
Cardiac arrhythmia may be caused by abnormal impulse
formation, abnormal impulse propagation, or both (Matyus
et al., 1997) it remains a major source of morbidity and
mortality in developed countries. For example, between 0.5
and 1 million North Americans and Europeans die each
year because of sudden cardiac death, which corresponds to
10–20% of all deaths among adults in the Western world
(Goldberger et al., 2008; Huikuri et al., 2001; Kromhout,
2007). In the past decade, the treatment of arrhythmia has
been dramatically altered by the development of non-
pharmacological therapies, such as targeted ablation of
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RESEARCHarrhythmogenic tissues and implantable cardioverter deﬁ-
brillators (ICDs), as well as the limited efﬁcacy and
proarrhythmic potential of conventional antiarrhythmic
(AA) drugs (Estrada and Darbar, 2008). AA drugs have
been classiﬁed by Vaughan Williams mainly based on their
effects on cardiac action potentials into classes I–IV and
later correlated to their effects on Na
? channel, b-recep-
tors, and K
? and Ca
2? channels (Hashimoto, 2007;
Vaughan Williams, 1992).
In the course of our studies directed to search for new
a1-AR antagonists, among which a series of (4-arylpi-
perazin-1-yl)propylpyrrolidin-2-one or 3-alkyl-3-phenyl-
pyrrolidin-2-one derivatives, it was shown that the
compounds obtained also showed marked AA and hyper-
tensive activities. The ED50 values determined for a num-
ber of them was lower than or comparable with the
reference compounds (Kulig et al., 2003, 2004, 2007,
2009; Malawska et al., 2002, 2005). For a large number of
chemometric analyses reported in medical research, there
are relatively few studies on the application of QSAR
analysis to AA species (Debnath et al., 2003; Fumagalli
et al., 2005; Pallavicini et al., 2006; Turabekova et al.,
2008). In this context, the aim of this study, being a part of
our drug design project, is to ﬁnd a model explaining the
AA activity of a series of 1-[3-(4-arylpiperazin-1-yl)pro-
pyl]pyrrolidin-2-one derivatives applying the quantitative
relationship between structural parameters and AA activity.
The quantitative structure–activity relationship (QSAR)
equation for our compounds is presented and discussed.
Computational methods
1-[3-(4-Arylpiperazin-1-yl)propyl]pyrrolidin-2-one
derivatives
Thirty-three analogs of 1-[3-(4-(aryl)piperazin-1-yl)pro-
pyl]pyrrolidin-2-one were chosen from the reports pub-
lished by us between 2002 and 2009 (Kulig et al., 2003,
2004, 2007, 2009; Malawska et al., 2002, 2005). The
source publications concern the synthesis of over 70 aryl-
piperazine derivatives and their pharmacological test
results. About 20 of these compounds display a lack of
a1-ARs activity and 40 compounds display a lack of AA
activity. These compounds are considered to be irrelevant
for the model formulation and they were excluded from the
current study. Thus, the set of the remaining 33 compounds
displaying both a1-ARs and AA activity are appropriate for
a QSAR analysis and are listed in Table 1. The external set
should include about 10–30% of the entire set and should
represent activities and structures that cover the whole
range of the training set (Gramatica, 2007). Consequently
the initial data set was split into two subsets: a training
subset (NTS = 25) and a external cross-validation subset
included randomly selected compounds number: 1, 3, 8,
17, 21, 23, 25, 30 (NEXT = 8).
Molecular descriptors and methods
In order to identify the effect of the molecular structure on
the AA activity a QSAR analysis of the selected com-
pounds was performed.
(1) The AA activity data expressed as ED50 (mg/kg) are
taken from the source publications and recalculated to
ED50 (mM/kg). Logarithmic values (-log ED50) are
listed in Table 1 as AA observed activity. Each ED50
(mg/kg) value was obtained from independent exper-
iments in adrenaline included arrhythmia in anaes-
thetized rats (Szekeres and Papp, 1975).
(2) For the molecular 3D structure calculations the
Gaussian 03 (version 6.1) package was used (Frisch
et al., 2004). The three-dimensional structures of the
pyrrolidin-2-one derivatives in their neutral state were
obtained through full optimization based on the AM1
quantum chemical procedure. Harmonic vibrational
analysis was used to ascertain whether the resulting
geometries were the true energy minima structures.
All the molecules were minimized until the root mean
square (RMS) gradient value was smaller than
10
-6 a.u. Next, resulting molecular 3D structure
was used for the calculation of the descriptors set
and to visualize the distribution of charge in a
molecule (the map of the electrostatic potential in the
form of a 3D plot). In order to obtain reliable
energetic and accurate data on electronic properties of
molecules the single-point energy calculations were
performed at the DFT/B3LYP level of theory using
the 6-31G** basis set. Suitable maps of the electro-
static potential were plotted based on the electronic
and nuclear charge distribution obtained from the
energy calculations results. The Gaussian suite of
programs calculates the electrostatic potential maps
and surfaces as the distribution of the potential energy
of unit positive charge in a given molecular space,
with a resolution controlled by the grid density. In
Fig. A in the Supplementary ﬁle representative plots
for extreme difference in the charge distribution
pattern are shown (Frisch et al., 1998; Leach, 2001).
(3) For the calculation of the descriptors the Talete srl,
DRAGON for Windows Version 5.5-2007 package
was used. Dragon descriptors include 22 different
logical blocks. The total number of calculated
descriptors was 3224. Several criteria were used to
reduce this number while optimizing the information
content of the descriptors set. First, descriptors for
374 Med Chem Res (2012) 21:373–381
123Table 1 Structures and afﬁnities for AA action of 1-[3-(4-arylpiperazin-1-yl)propyl]pyrrolidin-2-one derivatives used in the current work
Compounds AA activity R1 R2 R3
Observed Predicted
1
a 2.01 2.09 H H H
2 1.79 1.86 H 2-OMe H
3
a 1.80 1.79 H 2-Cl H
4 1.54 1.71 H 2-F H
5 2.52 2.24 H 2-OEt H
6 1.45 1.46 H 3-CF3 H
7 1.43 1.43 OH 2-OMe H
8
a 1.40 1.44 OH 4-Cl H
9 1.79 1.58 OH 2-F H
10 1.64 1.60 OH 3-OMe H
11 1.97 2.15 OH 2-OEt H
12 1.55 1.56 OH 2-Me H
13 2.23 2.21 OH 2-OH H
14 1.77 1.79 OH 2-OiPr H
15 1.31 1.31 OH 2-CF3 H
16 1.54 1.53 OH 2,4-diF H
17
a 1.48 1.32 OH 2-OMe, 5-Cl H
18 2.37 2.54 OH 2-OMe 3,3-diPh
19 2.13 2.17 OH 2-CF3 3,3-diPh
20 2.53 2.37 OH 2-Me 3,3-diPh
21
a 2.66 2.55 OH 2-OEt 3,3-diPh
22 2.38 2.33 OH H 3,3-diPh
23
a 1.60 1.88 OH H H
24 1.92 1.86 O(CO)NHEt 2-OMe H
25
a 2.19 1.99 O(CO)NHiPr 2-OMe H
26 1.52 1.56 O(CO)NHnPr 2-OMe H
27 1.77 1.81 O(CO)nPr 2-OiPr H
28 2.00 2.00 O(CO)NHiPr 2-Cl H
29 1.66 1.75 O(CO)NHEt H H
30
a 1.88 1.95 O(CO)iPr H H
31 1.47 1.51 O(CO)NHnB H H
32 1.52 1.42 O(CO)NHnPr H H
33 1.36 1.37 H 2-OH H
The AA expressed as -log ED50 values, in mM/kg
a Compounds excluded in the model generation procedures; external data set, AA observed activity by pharmacological tests, AA predicted
activity by Eq. 1
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123which no value was available for all the compounds
were disregarded. Second, descriptors of which the
value is constant (or near-constant) inside each group
of descriptors were excluded. For the remaining
descriptors, if two descriptors showed a correlation
coefﬁcient greater than 0.9, the one showing of the
highest pair correlation with the others descriptors
was removed. After these automatic screening proce-
dures, a set of 385 descriptors was obtained for
further analysis. To reduce the vast number of
descriptors to the 50 that correlated best with the
experimental data, the ‘‘Feature Selection and Vari-
able Screening’’ methods available in Statistica
(version 8.0) (2008) software were applied. Then, the
chosen descriptors were used as regressors of the
model: they are collected in Table A in the Supple-
mentary ﬁle and a detailed description of these
descriptors can be found in the literature (Todeschini
and Consonni, 2002).
Statistical analysis
The Multiple Linear Regression (MLR) (Allison, 1999)
and correlation analyses were carried out using the Statis-
tica (version 8.0) (2008) software. The forward stepwise
regression analysis yielded a three-parametric model
describing the biological activity as a function of molecular
descriptors. The statistical quality of the regression equa-
tions was evaluated by parameters such as the correlation
coefﬁcient R, the squared correlation coefﬁcient R
2, the
adjusted squared correlation coefﬁcient Radj
2 , the Root
Mean Squared Errors (RMSE) and the variance ratio
F. The statistical signiﬁcance (P level) of a result was
determined as P B 0.01 (Bland, 2000).
The model obtained in this study was validated by cal-
culations of the validated squared correlation coefﬁcient
(Q
2) values and prediction error sum of squares (called
SPRES) values. The Q
2 values were calculated from the
general internal cross-validation procedures ‘‘leave-one-
out’’ test (LOO) and ‘‘leave-many-out’’ test (LMO) and
external tests (EXT) (Baumann, 2005; Golbraikh and
Tropsha, 2002; Hawkins, et al., 2003; Kubinyi 1997a, b).
Abbreviations QLOO
2 , QLMO
2 , QEXT
2 (and QSLOO,Q S LMO,
QSEXT) have been used in their’s usual meaning for the
tests listed above. In addition, the robustness of the pro-
posed model was checked by permutation testing: parallel
models were developed based on a ﬁt to randomly reor-
dered Y-data (Y-scrambling, Y-randomization) (Gramatica,
2007; Tropsha, 2010; Tropsha et al., 2003). According to
the basic approach of Wold and Eriksson (1995) all ran-
domization methods consisted of ten randomization runs
for any data set size.
All computations were performed on a HP 6200 wx
workstation.
Results and discussion
Table 1 reports the observed AA activity, expressed as
-log ED50 (mM/kg) values in adrenaline included
arrhythmia in anaesthetized rats. All the tested compounds
showed AA stimulation as the –log ED50 values are
between 1.31 and 2.66.
In this study we have limited the number of presented
equations to this of the best regression model of the whole
set. The model is given as follows together with the
statistical and validation parameters:
AA ¼  60:167  13:005 ðÞ JGI4 þ 12:334  3:841 ðÞ PCR
þ 0:986  0:213 ðÞ Hy   20:110  6:072 ðÞ
ð1Þ
R ¼ 0:953; R2 ¼ 0:909; R2
adj ¼ 0:844; F ¼ 14:040;RM
SE ¼ 0:141;NTS ¼ 25;NEXT ¼ 8; P\0:01;Q2
LOO ¼ 0:744;
QSLOO ¼ 0:178; Q2
LMO ¼ 0:736; QSLMO ¼ 0:175; Q2
EXT ¼
0:858; QSEXT ¼ 0:168R2
Y ¼ 0:074; Q2
Y ¼ 0:022; where
N is the number of compounds included in the [training
(TS)/external (EXT)] data set, R the correlation coefﬁcient,
R
2 the squared correlation coefﬁcient, Radj
2 the adjusted
squared correlation coefﬁcient, RMSE the root mean
squared errors, F the variance ratio, P the signiﬁcance of
the variables in the model, QLOO
2 , QLMO
2 , QEXT
2 , RY
2, and QY
2
the correlation coefﬁcient of the adequate validation
methodologies.
The presented QSAR analysis yields a model incorpo-
rating three descriptors. Since the Topliss and Costello rule
(1972) allows the use of up to ﬁve descriptors for a training
set consisting of 25 compounds and the relation Radj
2 \R
2
is true, the model in not overparametrized. However, for
AA action we did not ﬁt any better correlation using more
descriptors in multi-parameter correlations. The correlation
coefﬁcient R of this relationship is 0.95 and explains up to
91% of all variance data for AA activity. Moreover, the
F test value together with RMSE at the P level of 1 9 10
-5
suggests that the equation has a good correlation with the
data and is statistically signiﬁcant. Every descriptor in the
regression equation must be independent. The correlation
between each descriptor was calculated and is presented in
form of a Pearson correlation matrix in Table 2. As can be
seen from these numbers all predictors have a pair corre-
lation minimal covariance \0.5 which assures that any
collinearity of predictors is not present. Table 1 reports the
AA activity predicted by Eq. 1. A plot of the predicted
activity versus the residual values was prepared to deter-
mine the existence of systematic errors in the model
376 Med Chem Res (2012) 21:373–381
123development (see Fig. B in the Supplementary ﬁle). The
uniform distribution of residues indicates no systematic
error (Belsley et al., 2005). The plots of observed AA
activities versus those predicted by Eq. 1 together with the
corresponding predicted intervals are shown in Fig. C in
the Supplementary ﬁle. Compound number 5 is out of 91%
prediction threshold and exhibits high AA activity in
contrast to other compounds of similar structure having
low hydrophobic factor i.e., compounds 2, 4–6. This inci-
dence may be explained by unique structural features. This
plot proves that the model as a good descriptive power.
Summing up the linear model seems to be adequately ﬁt to
the data, all predictors have P\0.01 and one can conclude
that all are independently associated with AA activity.
In an attempt to determine the utility of Eq. 1 as model
of AA activity four validation analyses were carried out
i.e., LOO, LMO, Y-scrambling, and external predictivity
(Kiralj and Ferreira, 2009). In the ﬁeld of statistical tech-
niques the LOO and LMO are used for internal validation.
From a theoretically acceptable model the R
2 cannot have
smaller values than QLOO
2 and QLMO
2 or QEXT
2 . Overall, the
best model is achieved when QLOO
2 B R
2 C QLMO
2 and
QLOO
2 & QLMO
2 . Commonly, QLOO
2 [0.5 is considered as
proof of the reasonably predictive capability of the equa-
tion. QLOO
2 [0.7 indicates the stable and predictive
potential of the equation. Nevertheless a high QLOO
2 value
does not indicate a high predictive power of the model. On
the other hand if R
2\QLOO
2 the model is overﬁtted. As can
be seen from the statistics presented next to Eq. 1 in our
case R
2[QLOO
2 , which means that our model is not
overﬁtted. The LMO test is usually used to verify results
obtained from the LOO test. In the QLMO
2 procedure ten
iterations were performed with ﬁve molecules left out in
each iteration (e.g., tenfold, 80/20 cross validation) (Kiralj
and Ferreira, 2009; Tropsha, 2010). The results of the LMO
test are collected in Table 3. On average, the overall test
steps R
2[QLMO
2 and QLOO
2 & QLMO
2 which is another
proof that the model is not underdetermined. In order to
ascertain whether the good results of the model described
by Eq. 1 are not due to chance correlation or structural
dependency of the training set, the Y-scrambling tests were
performed. The results of ten runs of Y-randomization tests
are shown in the Table 4. The average values are smaller
than 0.2, which, according to Wold and Eriksson (1995),
points to the absence of chance correlation (Kiralj and
Ferreira, 2009; Tropsha, 2010). The low RY
2 and QY
2 values
prove that our model is valid. To validate the predictive
power of the mathematical model more explicitly one
needs to conduct validation on the external set of data
(Gramatica, 2007; Kiralj and Ferreira, 2009). Therefore,
the EXT test was carried out on the groups of compounds
including 30% of the data set. As mentioned above, a
subset of eight randomly selected compounds was removed
from the entire set to be used in the validation procedure.
For external compounds (1, 3, 8, 17, 21, 23, 25, and 30)
QEXT
2 = 0.86 combined with the fact that there are no
outliers which exhibit a systematic error, conclusively
prove the good predictive potency of the quantitative
relationship constructed on the basis of the AA activity.
Thus, in our opinion, the derived models can be used for
the prediction of the AA commotion for new compounds in
a series of analogs. The 3-parametric equation deﬁnes the
best model for this subset of data. Molecular descriptors
incorporated in the equation are: JG4I, PCR, and Hy. All
Table 3 The results of the
LMO test
Number of runs Number of excluded
compounds in the LMO test
QLMO
2 QSLMO
1 26, 22, 33, 11, 20 0.76 0.18
2 13, 9, 33, 29, 22 0.82 0.12
3 20, 7, 32, 14, 24 0.71 0.21
4 24, 20, 9, 19, 16 0.74 0.17
5 29, 28, 32, 20, 33 0.66 0.21
6 24, 6, 18, 14, 19 0.73 0.16
7 24, 9, 13, 20, 16 0.67 0.20
8 16, 27, 20, 22, 13 0.69 0.21
9 22, 19, 14, 27, 9 0.87 0.09
10 14, 5, 32, 2, 13 0.71 0.19
Average values 0.74 0.17
Table 2 Pearson correlation matrix of the parameters used in this
study
JGI4 PCR Hy
JGI4 1.00
PCR 0.47 1.00
Hy 0.39 -0.22 1.00
JGI4 Mean topological charge index of order 4, PCR ratio of multiple
path count over path count, Hy hydrophilic factor
Med Chem Res (2012) 21:373–381 377
123the obtained descriptors belong to different logical blocks
of descriptors such as the Topological charge indices (TCI)
(JGI4), (Ga ´lvez et al., 1996, 1995, 1994; Rios-Santamarina
et al., 1998). The Walk and path counts (PCR) (Diudea
et al., 1994; Randic, 1980; Razinger, 1986;R u ¨cker and
Ru ¨cker, 1993, 2000), and the Molecular properties (Hy)
(Todeschini et al., 1997). Brief detailed descriptions of
these descriptors can be found in the literature (Todeschini
and Consonni, 2002). The obtained model incorporates
descriptors of rather structural nature due to the regression
coefﬁcient value (see Eq. 1). As can be easily noticed, the
descriptors inﬂuencing the investigated properties the most
are JG4I and PCR. All descriptors related to physico-
chemical properties of the molecule (except two) were
excluded during the statistical analysis (Table A in the
Supplementary ﬁle). This means that the structure and
geometry of the molecule affect the AA activity, rather
than its physico-chemical properties. Looking more closely
at the chosen descriptors and their statistics in Table 5 JGI4
and PCR have |BETA|[1 (Achen, 1982).
The molecular charge distribution plays an important
role in many biological and pharmacological activities.
Kier and Hall (1999) developed the concept of E-states, an
electrotopological-state index for atoms in a molecule. For
calculating TCI descriptors, H-depleted molecular structure
is represented as a graph G. TCI are calculated using the
‘‘inverse square topological distance matrix’’ where the
charge inﬂuence decreases with the square of the distance.
Ga ´lvez et al. (1996, 1995) introduced the ‘‘inverse square
topological distance matrix’’ denoted by D* in which
matrix elements are the inverse square of the corresponding
element in the topological distance matrix D. The diagonal
entries of the topological distance matrix remain the same,
so diagonal entries of D* are 0. Finally,
JGIk ¼
GGIk
N   1 ðÞ
and GGIk ¼
X i¼N 1;j¼N
i¼1;j¼iþ1
CTi;j
       dðk; Di;jÞ;
ð2Þ
where, d is where d is Kronecker’s delta and CTij = mij-
mji [m stands for the elements of the M matrix
M = A 9 D*; A is the adjacency (N 9 N) matrix of the
molecular graph G, where N is the number of vertices
(atoms different to hydrogen)]. Thus, GGIk represents the
sum of all the CTij terms, with Dij = k, being Dij the entries
of the topological distance matrix (D) and k ranging from 1
up to 10. These indexes represent a strictly topological
quantity plausibly correlating with the charge distribution
inside the molecule.
In other words, the TCI estimates the charge transfer
between pair of atoms, and hence the global charge transfer
in the molecule. The JGI4 parameter varies within the
investigated set from 0.040 (compound 1, unsubstituent) to
0.016 (compound 17, for which R1-OH, R2-2-OMe, 5-Cl,
Table 4 RY
2 and QY
2 values after ten Y-scrambling tests
Number of runs Order of compounds in observed y vector in the Y-scrambling test RY
2 QY
2
1 9, 4, 32, 24, 19, 27, 12, 33, 29, 11, 22, 26, 15, 6, 20, 14, 28, 5, 31, 16, 13, 10, 2, 18, 7 0.07 0.01
2 12, 19, 14, 9, 26, 20, 33, 16, 32, 28, 24, 22, 27, 29, 5, 10, 4, 6, 18, 7, 2, 31, 11, 15, 13 0.12 0.05
3 16, 19, 22, 33, 11, 6, 2, 7, 26, 4, 5, 24, 31, 15, 10, 20, 29, 14, 27, 13, 28, 12, 32, 18, 9 0.06 0.02
4 28, 12, 4, 20, 15, 11, 24, 2, 9, 7, 31, 6, 29, 18, 16, 26, 19, 22, 14, 33, 5, 27, 10, 32, 13 0.06 0.01
5 32, 2, 16, 20, 6, 22, 19, 15, 14, 5, 26, 29, 7, 4, 18, 12, 28, 11, 10, 33, 31, 27, 9, 24, 13 0.09 0.01
6 32, 19, 13, 12, 6, 20, 28, 10, 27, 31, 33, 16, 7, 14, 11, 29, 24, 15, 26, 4, 5, 9, 2, 22, 18 0.08 0.05
7 15, 31, 2, 20, 27, 9, 28, 13, 19, 12, 33, 24, 7, 14, 11, 29, 5, 16, 22, 32, 18, 26, 10, 6, 4 0.04 0.00
8 7, 28, 10, 31, 11, 22, 19, 29, 33, 12, 27, 18, 32, 20, 6, 13, 2, 9, 5, 15, 26, 4, 24, 14, 16 0.03 0.00
9 27, 29, 24, 33, 28, 4, 19, 31, 32, 12, 9, 14, 13, 7, 18, 22, 26, 5, 20, 11, 16, 10, 15, 6, 2 0.05 0.00
10 27, 6, 10, 2, 14, 31, 19, 29, 32, 4, 26, 11, 18, 12, 9, 13, 15, 24, 28, 33, 16, 5, 22, 7, 20 0.13 0.07
Average values 0.07 0.02
Table 5 Multiple regression results
BETA Standard error B Standard error t(14) P level
Intercept -20.1101 6.07174 -3.31209 0.005137
JGI4 -0.870898 0.188244 -60.1674 13.00513 -4.62644 0.000392
PCR 1.026828 0.319750 12.3345 3.84092 3.21134 0.006277
Hy 0.604621 0.130843 0.9856 0.21329 4.62095 0.000396
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123and R3-H). In Fig. A in the Supplementary ﬁle, the dif-
ferences in the distribution of the electrostatic charge in
compounds 1 and 17 are visualized. Because the sign of the
regression coefﬁcient is negative, an increase of this pre-
dictor values will result in a decrease in AA activity. This
suggests that some unique charge distribution is needed for
increase AA activity.
The PCR descriptor is related to the molecular com-
plexity of the graph (Trinajstic, 1992) i.e., to molecular
branching and size as derived from the ratio of multiple
path count over path count and it is sensitive to the sub-
stituent position within the investigated set as it varies from
1.182 (compound 31, for which O(CO)NHnB substituent
R1 and H substituted R2 and R3) to 1.309 (complex
derivative 21, for which of R1-OH, R2-2-OEt and R3-3,
3-diPh). Because the sign of the regression coefﬁcient is
positive, a decrease of this predictor will result in a
decrease in AA stimulation. Our earlier qualitative inves-
tigations (SAR) led us to similar conclusions (Kulig et al.,
2007; Nowaczyk et al., 2009, 2010). The remaining
parameter of the model (Hy) is the hydrophilic factor. It is
a simple empirical index related to the hydrophilicity of
compounds. In our data set the Hy index varies between
-0.8 and 0.4. According to the sign of the BETA coefﬁ-
cient (Table 5), an increase in the hydrophilicity of the
compounds will result in an increase in the predicted fea-
ture, although the relatively low absolute BETA values
indicate that their signiﬁcance in the model is not crucial.
Conclusions
In this study we have developed a mathematical model
for the prediction of the AA activity of a series of 1-[3-
(4-arylpiperazin-1-yl)propyl]pyrrolidin-2-ones containing
various substituents on the aryl, propyl, and pyrrolidin-
2-one moieties. The resulting model displays a good ﬁt
with the experimental data, with a correlation coefﬁcient of
0.95 and explains up to 91% of the variance. In addition,
the cross-validation coefﬁcients reﬂecting the predictive
power of the regression, QLOO
2 is 0.74, and QLMO
2 is 0.74.
The Y-scrambling test proved that the good statistics
obtained for Eq. 1 are not due to chance correlation or
structural dependency of the training set. In addition, the
external test showed a QEXT
2 of 0.86 which proves a good
predictability of the AA by the model (Eq. 1). The main
purpose of this investigation was to determine the param-
eters which best describe the biological activity of a
number of arylpiperazines derivatives. The results obtained
here show that the activity of these compounds is mainly
determined by the JGI4-, PCR- , and Hy-values. The model
provides important information on the structure–activity
relationships of these types of compounds at the molecular
level relevant for the design of new AA derivatives. The
JGI4 of a potent agent should be as low as possible while
PCR- and Hy-values should be high. On the basis of these
results in combination with previous evidences we can
conclude that the interaction of the 1-[3-(4-arylpiperazin-1-
yl)propyl]pyrrolidin-2-one moiety with the arrhythmic
species is greatly increased by the structure and the
geometry of the molecule rather than its physico-chemical
properties. More extensive in silico studies are in progress
and will be reported in due course.
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